Find stories of hope, told by the people who motivate us every day to continue changing the standard in cancer care.
Each cell therapy we develop is uniquely designed for each patient, harnessing the power of the immune system to target and attack cancer. Our CAR T-cell therapy manufacturing process includes these 5 steps:
November 03, 2025
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025October 13, 2025
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025August 21, 2025
Kite to Acquire Interius BioTherapeutics to Advance In Vivo PlatformJune 01, 2025
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025